Find a Tender
complete
Official procurement procedure
(NU/1433-40) Transdermal Drug Delivery: The Provision of Business Consultancy to Assist Commercialisation of University Research.
Business and management consultancy and related services
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Newcastle University: "(NU/1433-40) Transdermal Drug Delivery: The Provision of Business Consultancy to Assist Commercialisation of University Research.". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Newcastle University | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Newcastle University
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Newcastle University. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
2.4Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 104 active published awards; 98 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNewcastle University | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSDynamic market | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published13 Jan 2023, 10:29 GMT | Last source update13 Jan 2023, 10:29 GMT | Recurring procurementNot published |
ClassificationBusiness and management consultancy and related services | ||
Delivery area | ||
OCIDocds-h6vhtk-039727 | ||
What is being bought
The Northumbria University team have developed a new technology to move drugs into the body from a layer in a patch stuck to the skin.
This is an alternative to using needles. Current drug delivery patches don’t work for a large proportion of drugs because of their chemistry characteristics mean they don’t absorb through skin well. This technology can move ‘difficult’ molecules through the skin.
The initial brief of the executive will be to:
(1) Produce a viable 5 year business plan;
(2) Obtain university approval for the venture;
a. Act for the company in the spin-out legal process and address all company formation matters;
b. Provide to the appropriate university all matters necessary for Research England reporting requirements;
(3) Secure a Medical Device Manufacturer partnership
(4) Engage with investors in securing funding
What changed
From the official release history
- Status changed to complete
13 Jan 2023, 10:29 GMT - Official notice release published
13 Jan 2023, 10:29 GMT - Buyer information updated
13 Jan 2023, 10:29 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedThe Northumbria University team have developed a new technology to move drugs into the body from a layer in a patch stuck to the skin. This is an alternative to using needles. Current drug delivery patches don’t work for a large proportion of drugs because of their chemistry characteristics mean they don’t absorb through skin well. This technology can move ‘difficult’ molecules through the skin. The initial brief of the executive will be to: (1) Produce a viable 5 year business plan; (2) Obtain university approval for the venture; a. Act for the company in the spin-out legal process and address all company formation matters; b. Provide to the appropriate university all matters necessary for Research England reporting requirements; (3) Secure a Medical Device Manufacturer partnership (4) Engage with investors in securing fundingContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
13 Jan 2023, 10:29 GMT - Award active
Not published · Not published - Contract active
Signed 19 Dec 2022, 00:00 GMT · £30,000
Commercial outcome and competition
Awards Dr Peter Arnold Not published · Not published · active |
Contracts Contract £30,000 · signed 19 Dec 2022, 00:00 GMT · active |
Bid statistics bids: 3 (lot 1) electronicBids: 3 (lot 1) foreignBidsFromNonEU: 3 (lot 1) smeBids: 3 (lot 1) |
Buyer and organisations in this procedure
Newcastle University
Contracting authority GB-FTS-168Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleNot published |